Immune checkpoint inhibitors (ICIs) have remarkably modified the way solid tumors are managed, including breast cancer. Unfortunately, only a relatively small number of breast cancer patients significantly respond to these treatments. To maximize the immunotherapy benefit in breast cancer, several efforts are currently being put forward for the identification of i) the best therapeutic strategy (i.e. ICI monotherapy or in association with chemotherapy, radiotherapy, or other drugs); ii) the optimal timing for administration (e.g. early/advanced stage of disease; adjuvant/neoadjuvant setting); iii) the most effective and reliable predictive biomarkers of response (e.g. tumor-infiltrating lymphocytes, programmed death-ligand 1, microsatellite instability associated with mismatch repair deficiency, and tumor mutational burden). In this article, we review the impacts and gaps in the characterization of immune-related biomarkers raised by clinical and translational research studies with immunotherapy treatments. Particular emphasis has been put on the documented evidence of significant clinical benefits of ICI in different randomized clinical trials, along with preanalytical and analytical issues in predictive biomarkers pathological assessment.
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology / C. Criscitiello, E. Guerini-Rocco, G. Viale, C. Fumagalli, E. Sajjadi, K. Venetis, R. Piciotti, M. Invernizzi, U. Malapelle, N. Fusco. - (2021 May).
|Titolo:||Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology|
FUSCO, NICOLA (Corresponding)
|Parole Chiave:||breast cancer; biomarkers; immunotherapy; TILs; PD-L1; mismatch repair; microsatellite instability; tumor mutational burden|
|Settore Scientifico Disciplinare:||Settore MED/08 - Anatomia Patologica|
Settore MED/06 - Oncologia Medica
|Data di pubblicazione:||2021-05|
|Appare nelle tipologie:||24 - Pre-print|
File in questo prodotto:
|Criscitiello et al - ACAMC - Manuscript_PREPRINT.pdf||Pre-print (manoscritto inviato all'editore)||Open Access Visualizza/Apri|